BR112014007788A2 - compostos de pirrolopirimidina para tratamento do câncer - Google Patents
compostos de pirrolopirimidina para tratamento do câncerInfo
- Publication number
- BR112014007788A2 BR112014007788A2 BR112014007788A BR112014007788A BR112014007788A2 BR 112014007788 A2 BR112014007788 A2 BR 112014007788A2 BR 112014007788 A BR112014007788 A BR 112014007788A BR 112014007788 A BR112014007788 A BR 112014007788A BR 112014007788 A2 BR112014007788 A2 BR 112014007788A2
- Authority
- BR
- Brazil
- Prior art keywords
- mer
- cancer treatment
- pyrrolopyrimidine compounds
- lla
- compound
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000005014 ectopic expression Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542392P | 2011-10-03 | 2011-10-03 | |
| US201161547183P | 2011-10-14 | 2011-10-14 | |
| PCT/US2012/058298 WO2013052417A1 (en) | 2011-10-03 | 2012-10-01 | Pyrrolopyrimidine compounds for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014007788A2 true BR112014007788A2 (pt) | 2017-04-18 |
Family
ID=48044101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014007788A BR112014007788A2 (pt) | 2011-10-03 | 2012-10-01 | compostos de pirrolopirimidina para tratamento do câncer |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9273056B2 (enExample) |
| EP (1) | EP2763988B1 (enExample) |
| JP (2) | JP2014532060A (enExample) |
| KR (1) | KR102063098B1 (enExample) |
| CN (1) | CN103958510B (enExample) |
| AU (1) | AU2012318896B2 (enExample) |
| BR (1) | BR112014007788A2 (enExample) |
| CA (1) | CA2850617A1 (enExample) |
| ES (1) | ES2650630T3 (enExample) |
| IL (1) | IL231835A0 (enExample) |
| MX (1) | MX2014004086A (enExample) |
| RU (1) | RU2631655C2 (enExample) |
| WO (1) | WO2013052417A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| CN103958510B (zh) | 2011-10-03 | 2016-10-19 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的吡咯并嘧啶化合物 |
| BR112014028424A2 (pt) | 2012-05-22 | 2018-04-24 | Univ North Carolina Chapel Hill | compostos de pirimidina para o tratamento de câncer |
| EP3184121A3 (en) | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases |
| EP2909211A4 (en) | 2012-10-17 | 2016-06-22 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| CA2945128A1 (en) * | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrimidine compounds |
| CN106188060A (zh) * | 2015-04-29 | 2016-12-07 | 厦门大学 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| US20180296561A1 (en) * | 2015-10-07 | 2018-10-18 | The University Of North Carolina At Chapel Hill | The Methods For Treatment Of Tumors |
| US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| PT3436461T (pt) | 2016-03-28 | 2024-01-23 | Incyte Corp | Compostos de pirrolotriazina como inibidores de tam |
| IL265028B (en) * | 2016-09-16 | 2022-09-01 | Vitae Pharmaceuticals Llc | Inhibitors of the menin-mil interaction |
| WO2018094227A1 (en) | 2016-11-17 | 2018-05-24 | The University Of North Carolina At Chapel Hill | Alkyl pyrrolopyrimidine analogs and methods of making and using same |
| US10633387B2 (en) | 2017-09-27 | 2020-04-28 | Incyte Corporation | Salts of TAM inhibitors |
| WO2019113190A1 (en) | 2017-12-07 | 2019-06-13 | Array Biopharma Inc. | Bicyclic fused pyridine compounds as inhibitors of tam kinases |
| US11407757B2 (en) * | 2017-12-28 | 2022-08-09 | Development Center For Biotechnology | Heterocycle compounds as Tyro3, Axl and MerTK (TAM) family of receptor tyrosine kinase inhibitors |
| SI3813800T1 (sl) | 2018-06-29 | 2025-07-31 | Incyte Corporation | Formulacije zaviralca axl/mer |
| KR102163494B1 (ko) * | 2018-10-26 | 2020-10-08 | 한국과학기술연구원 | 단백질 키나아제 저해제인 헤테로방향족 매크로시클릭 유도체 |
| KR102848297B1 (ko) * | 2019-04-02 | 2025-08-20 | 메릭스 인코포레이티드 | 키나아제 억제제의 다형체, 이러한 화합물을 함유하는 약학 조성물, 제조 방법 및 용도 |
| JP2023516441A (ja) | 2020-03-06 | 2023-04-19 | インサイト・コーポレイション | Ａｘｌ／ｍｅｒ阻害剤及びｐｄ－１／ｐｄ－ｌ１阻害剤を含む併用療法 |
| CN112043710A (zh) * | 2020-09-28 | 2020-12-08 | 广州智睿医药科技有限公司 | 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物 |
| CN115073469B (zh) * | 2021-03-15 | 2023-12-22 | 药雅科技(上海)有限公司 | 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用 |
| WO2025170773A1 (en) * | 2024-01-26 | 2025-08-14 | The University Of North Carolina At Chapel Hill | Tam-family degraders and uses thereof |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| AU3176297A (en) * | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| AR035885A1 (es) * | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| US7217710B2 (en) | 2001-10-02 | 2007-05-15 | Smithkline Beecham Corporation | Substituted pyrazolopyrimidines |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| ES2304252T3 (es) | 2003-05-28 | 2008-10-01 | Universita Degli Studi Di Siena | Derivados sustituidos en posicion 4 de pirazolo(3,4-d)pirimidina y utilizaciones de los mismos. |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| GB0320728D0 (en) | 2003-09-04 | 2003-10-08 | Kilminster Shaun | Test |
| EP2145888A1 (en) | 2003-09-18 | 2010-01-20 | Conforma Therapeutics Corporation | Deazapurine derivatives as HSP90-Inhibitors |
| WO2005072826A2 (en) | 2004-01-21 | 2005-08-11 | Emory University | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection |
| CA2553724A1 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| CN1918158B (zh) | 2004-02-14 | 2011-03-02 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| JPWO2005095382A1 (ja) | 2004-03-30 | 2007-08-16 | 協和醗酵工業株式会社 | 抗腫瘍剤 |
| EP1732541A4 (en) * | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| JP5008567B2 (ja) | 2004-09-30 | 2012-08-22 | テイボテク・フアーマシユーチカルズ | Ｈｉｖ阻害性５−ヘテロシクリルピリミジン |
| WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
| WO2007035963A2 (en) * | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| TWI333953B (en) | 2005-10-06 | 2010-12-01 | Schering Corp | Pyrazolopyrimidines as protein kinase inhibitors |
| EP1957539B1 (en) | 2005-12-08 | 2013-04-17 | Medarex, Inc. | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use |
| JP2009520028A (ja) | 2005-12-19 | 2009-05-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Ｉｇｆｒ抑制剤および抗癌剤の併用 |
| EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
| AU2007233737B2 (en) | 2006-03-30 | 2012-11-29 | Janssen Sciences Ireland Uc | HIV inhibiting 5-amido substituted pyrimidines |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| DK2212297T3 (da) | 2007-10-12 | 2011-09-05 | Ingenium Pharmaceuticals Gmbh | Inhibitorer af proteinkinaser |
| EP2219671A4 (en) * | 2007-11-09 | 2011-02-09 | Salk Inst For Biological Studi | USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8399206B2 (en) | 2008-07-10 | 2013-03-19 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| US8569466B2 (en) | 2008-09-10 | 2013-10-29 | Nnochiri Ekwuribe | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers |
| TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| GB0819105D0 (en) * | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
| US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| US8765727B2 (en) | 2009-01-23 | 2014-07-01 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| TW201102391A (en) * | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| TW201040162A (en) | 2009-05-06 | 2010-11-16 | Portola Pharm Inc | Inhibitors of JAK |
| JP5883384B2 (ja) | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫機能を調節する方法 |
| WO2011029915A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
| WO2011065800A2 (ko) | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
| WO2011103441A1 (en) | 2010-02-18 | 2011-08-25 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| JP2014005206A (ja) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| CN103221048A (zh) | 2010-11-18 | 2013-07-24 | 卡斯纳莱拉创新药物私人有限公司 | 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法 |
| US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2012311184A1 (en) | 2011-09-22 | 2014-03-06 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
| CN103958510B (zh) | 2011-10-03 | 2016-10-19 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的吡咯并嘧啶化合物 |
| JP2015509943A (ja) | 2012-02-21 | 2015-04-02 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ウイルス侵入補助因子としてのｔａｍレセプター |
| JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| BR112014028424A2 (pt) | 2012-05-22 | 2018-04-24 | Univ North Carolina Chapel Hill | compostos de pirimidina para o tratamento de câncer |
| EP2909211A4 (en) | 2012-10-17 | 2016-06-22 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| US20170202847A1 (en) | 2014-04-04 | 2017-07-20 | The University Of North Carolina At Chapel Hill | Methods for the treatment of tumors |
| CA2945128A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrimidine compounds |
-
2012
- 2012-10-01 CN CN201280056825.4A patent/CN103958510B/zh active Active
- 2012-10-01 ES ES12839069.7T patent/ES2650630T3/es active Active
- 2012-10-01 CA CA2850617A patent/CA2850617A1/en not_active Abandoned
- 2012-10-01 JP JP2014534626A patent/JP2014532060A/ja active Pending
- 2012-10-01 WO PCT/US2012/058298 patent/WO2013052417A1/en not_active Ceased
- 2012-10-01 BR BR112014007788A patent/BR112014007788A2/pt not_active IP Right Cessation
- 2012-10-01 EP EP12839069.7A patent/EP2763988B1/en active Active
- 2012-10-01 US US14/348,805 patent/US9273056B2/en active Active
- 2012-10-01 MX MX2014004086A patent/MX2014004086A/es unknown
- 2012-10-01 KR KR1020147010156A patent/KR102063098B1/ko active Active
- 2012-10-01 AU AU2012318896A patent/AU2012318896B2/en active Active
- 2012-10-01 RU RU2014115847A patent/RU2631655C2/ru active
-
2014
- 2014-03-31 IL IL231835A patent/IL231835A0/en unknown
-
2016
- 2016-02-03 US US15/014,573 patent/US9795606B2/en active Active
- 2016-12-28 JP JP2016255095A patent/JP6316925B2/ja active Active
-
2017
- 2017-10-23 US US15/790,700 patent/US10179133B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6316925B2 (ja) | 2018-04-25 |
| WO2013052417A1 (en) | 2013-04-11 |
| CN103958510A (zh) | 2014-07-30 |
| US20180104247A1 (en) | 2018-04-19 |
| US9273056B2 (en) | 2016-03-01 |
| MX2014004086A (es) | 2014-09-22 |
| US20140243315A1 (en) | 2014-08-28 |
| RU2014115847A (ru) | 2015-11-10 |
| KR20140095471A (ko) | 2014-08-01 |
| CA2850617A1 (en) | 2013-04-11 |
| US20160151372A1 (en) | 2016-06-02 |
| ES2650630T3 (es) | 2018-01-19 |
| IL231835A0 (en) | 2014-05-28 |
| JP2017101043A (ja) | 2017-06-08 |
| US9795606B2 (en) | 2017-10-24 |
| KR102063098B1 (ko) | 2020-01-08 |
| RU2631655C2 (ru) | 2017-09-26 |
| AU2012318896B2 (en) | 2017-03-02 |
| AU2012318896A1 (en) | 2014-05-22 |
| EP2763988B1 (en) | 2017-09-20 |
| EP2763988A4 (en) | 2015-06-03 |
| JP2014532060A (ja) | 2014-12-04 |
| HK1201256A1 (en) | 2015-08-28 |
| EP2763988A1 (en) | 2014-08-13 |
| CN103958510B (zh) | 2016-10-19 |
| US10179133B2 (en) | 2019-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014007788A2 (pt) | compostos de pirrolopirimidina para tratamento do câncer | |
| CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
| SA521420965B1 (ar) | A2a/a2b مشتقات بيرازين مدمجة في صورة مثبطات | |
| BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
| CY1121763T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CY1120866T1 (el) | Παρεμποδιστες dna-pk | |
| CY1118771T1 (el) | Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων | |
| UY33539A (es) | Compuestos químicos alk | |
| CO7170165A2 (es) | Fabricación de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acético | |
| DOP2014000058A (es) | 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante | |
| MA34066B1 (fr) | Composes de la pyrrolopyrimidine utilises en tant qu'inhibiteurs des cdk4/6 | |
| CU24335B1 (es) | Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer | |
| BR112015014090A2 (pt) | intensificador de inibidores de zeste homólogo 2 | |
| MX374513B (es) | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. | |
| EA201270373A1 (ru) | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли | |
| BR112012010186B8 (pt) | derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos | |
| BR112015027951A2 (pt) | arilquinazolinas | |
| CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
| MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
| DOP2014000012A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| BR112012029647A2 (pt) | novos derivados de pirimidinas | |
| BR112013029999A2 (pt) | derivados de tiazol | |
| MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
| ECSP088828A (es) | 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2534 DE 30-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |